Decreased bone mineral density and periodontal management

Periodontology 2000

Volumn 61, Issue 1, 2013, Pages 195-218

  Reddy, Michael S ^a   Morgan, Sarah L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT;

AGING; ALVEOLAR BONE LOSS; ARTICLE; BONE DENSITY; BONE REMODELING; FRACTURE; HUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PERIODONTAL DISEASE; PHYSIOLOGY; RISK FACTOR;

AGING; ALVEOLAR BONE LOSS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; PERIODONTAL DISEASES; RISK FACTORS;

EID: 84871244263     PISSN: 09066713     EISSN: 16000757     Source Type: Journal    
DOI: 10.1111/j.1600-0757.2011.00400.x     Document Type: Article

References (161)

1. Adler R. Epidemiology and pathophysiology of osteoporosis in men. Curr Osteoporos Rep 2006: 4: 110-115.
2. Allende-Vigo M. The use of biochemical markers of bone turnover in osteoporosis. P R Health Sci J 2007: 26: 91-95.
3. 3 in humans. J Clin Endocrinol Metab 2004: 89: 5387-5391.
4. Atwood D. Bone loss of edentulous alveolar ridges. J Periodontol 1979: 50: 11-21.
5. Barrett-Connor E, Siris ES, Wehren L, Miller PD, Abbott TA, Berger ML, Santora AC, Sherwood LM. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 2005: 20: 185-194.
6. Barros S, Silva M, Somerman M, Nociti FJ. Parathyroid hormone protects against periodontitis-associated bone loss. J Dent Res 2003: 82: 791-795.
7. Berardi D, Carlesi T, Rossi F, Calderini M, Volpi R, Perfetti G. Potential applications of biphosphonates in dental surgical implants. Int J Immunopathol Pharmacol 2007: 20: 455-465.
8. Binkley N, Lewiecki EM. Vitamin D and common sense. J Clin Densitometry 2011: 2: 95-99.
9. Bischoff-Ferrari H, Dawson-Hughes B. Where do we stand on vitaminD? Bone 2007: 41: S13-S19.
10. Bischoff-Ferrari H, Willett W, Wong J, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitaminD supplementation: a meta-analysis of randomized controlled trials. J Am Med Assoc 2005: 293: 2257-2264.
11. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, for the Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996: 347: 1535-1541.
12. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, for the Fit Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000: 85: 4118-4124.
13. Blake G, Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom 2007: 10: 102-110.
14. Bonnick S. Osteoporosis in men and women. Clin Cornerstone 2006: 8: 28-39.
15. Boonen S, Kaufman J, Goemaere S, Bouillon R, Vanderschueren D. The diagnosis and treatment of male osteoporosis: defining, assessing, and preventing skeletal fragility in men. Eur J Intern Med 2007: 18: 6-17.
16. Bouxsein M, Szulc P, Munoz F, Thrall E, Sornay-Rendu E, Delmas P. Contribution of trochanteric soft tissues to fall force estimates, the factor of risk, and prediction of hip fracture risk. J Bone Miner Res 2007: 22: 825-831.
17. Brennan-Calanan RM, Genco RJ, Wilding GE, Hovey KM, Trevisan M, Wactawski-Wende J. Osteoporosis and oral infection: independent risk factors for oral bone loss. J Dent Res 2008: 87: 323-327.
18. Broe K, Chen T, Weinberg J, Bischoff-Ferrari H, Holick M, Kiel D. A higher dose of vitaminD reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. J Am Geriatr Soc 2007: 55: 234-239.
19. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002: 71: 103-111.
20. Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007: 22: 465-475.
21. Canalis E, Giustina A, Bilezikian J. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007: 357: 905-916.
22. Cartos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714, 217 people. J Am Dent Assoc 2008: 139: 23-30.
23. Cauley J. Osteoporosis in men: prevalence and investigation. Clin Cornerstone 2006: 8(Suppl. 3): S20-S25.
24. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, NG KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001: 65: 125-134.
25. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB, for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. J Am Med Assoc 2003: 290: 1729-1738.
26. Centers for Disease Control and Prevention. Total tooth loss among persons aged greater than or equal to 65years - selected states, 1995-1997. MMWR Morb Mortal Wkly Rep 1999: 48: 206-210.
27. Chesnut CH III, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int 2008: 19: 479-491.
28. Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D, for the PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000: 109: 267-276.
29. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004: 19: 1241-1249.
30. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomason CA, Khandekar J, Petrovitch H, McTiernan A, WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Ransdomized Trial. J Am Med Assoc 2003: 289: 3243-3253.
31. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993: 94: 646-650.
32. Cooper C. Epidemiology of osteoporosis. In: Favus MJ, editor. Primer on the metabolic bone disease and disorders of mineral metabolism. Washington DC: American Society for Bone and Mineral Research, 2003: 307-313.
33. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ, for the Fracture Intervention Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998: 280: 2077-2082.
34. Cummings S, Eckert S, Krueger K, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. J Am Med Assoc 1999: 281: 2189-2197.
35. Cummings S, Nevitt M, Browner W, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM, for the Study of Osteoporotic Fractures Research Group. Risk factors for hip fracture in white women. N Engl J Med 1995: 332: 767-773.
36. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009: 361: 756-765.
37. Davis CD, Hartmuller V, Freedman DM, Hartge P, Picciano MF, Swanson CA, Milner JA. VitaminD and cancer: current dilemmas and future needs. Nutr Rev 2007: 65: S71-S74.
38. Dawson-Hughes B, Tosteson ANA, Melton LJ III, Baim S, Favus MJ, Khosla S, Lindsay RL. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008: 19: 449-458.
39. De Vries F, Bracke M, Leufkens H, Lammers J, Cooper C, Van Staa T. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007: 56: 208-214.
40. Delmas P, Bjarnason N, Mitlak B, Delmas PD, Bjarnason NH, Mitlak BH, Ravoux C, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997: 337: 1641-1647.
41. Delmas P, Marin F, Marcus R, Misurski D, Mitlak B. Beyond hip: importance of other nonspinal fractures. Am J Med 2007: 120: 381-387.
42. Delmas P, Rizzoli R, Cooper C, Reginster J. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 2005: 16: 1-5.
43. Dennison E, Mohamed M, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin North Am 2006: 32: 617-629.
44. Department of Health and Human Services. Bone health and osteoporosis. A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, 2004.
45. Duarte P, Gonçalves P, Sallum A, Sallum E, Casati M, Humberto Nociti FJ. Effect of an estrogen-deficient state and its therapy on bone loss resulting from an experimental periodontitis in rats. J Periodontal Res 2004: 39: 107-110.
46. Eggertsen R, Mellström D. Height loss in women caused by vertebral fractures and osteoporosis. Ups J Med Sci 2007: 112: 213-219.
47. Elders PJ, Habets LL, Netelenbos JC, van der Linden LW, van der Stelt PF. The relation between periodontitis and systemic bone mass in women between 46 and 55years of age. J Clin Periodontol 1992: 19: 492-496.
48. Ensrud K, Barrett-Connor E, Schwartz A, Ensrud KE, Barrett-Connor L, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberh MC, Torner JC, Lombardi A, Black DM, for the Fracture Intervention Trial Long-Term Extension Research Group. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004: 19: 1259-1269.
49. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant K, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, for the Multiple Outcomes of Raloxifene Evaluation Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999: 282: 637-645.
50. Gallacher S, Gallagher A, McQuillian C, Mitchell P, Dixon T. The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures. Osteoporos Int 2007: 18: 185-192.
51. Gehlbach S, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood J. Recognition of vertebral fracture in a clinical setting. Osteoporos Int 2000: 11: 577-582.
52. Geraets WG, Verheij JG, van der Stelt PF, Horner K, Lindh C, Nicopoulou-Karayianni K, Jacobs R, Harrison EJ, Adams JE, Devlin H. Prediction of bone mineral density with dental radiographs. Bone 2007: 40: 1217-1221.
53. Geurs NC, Lewis CE, Jeffcoat MK. Osteoporosis and periodontal disease progression. Periodontol 2000 2003: 32: 105-110.
54. Grant B, Amenedo C, Freeman K, Kraut R. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 2008: 66: 223-230.
55. Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF, for the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial. J Am Dent Assoc 2008: 139: 32-40.
56. Gullberg B, Johnell O, Kanis J. World-wide projections for hip fracture. Osteoporos Int 1997: 7: 407-413.
57. Harris RP, Grady WS. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the US Preventive Services Task Force. Ann Intern Med 2005: 142: 855-860.
58. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD, for the Vertebral Efficacy With Risedronate Therapy Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. J Am Med Assoc 1999: 282: 1344-1352.
59. Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, Weaver C. Peak bone mass. Osteoporos Int 2000: 11: 985-1009.
60. Heaney R, Dowell M, Barger-Lux M. Absorption of calcium as the carbonate and citrate salts, with some observations on method. Osteoporos Int 1999: 9: 19-23.
61. Heaney R, Dowell M, Bierman J, Hale C, Bendich A. Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr 2001: 20: 239-246.
62. Heller H, Greer L, Haynes S, Poindexter J, Pak C. Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women. J Clin Pharmacol 2000: 40: 1237-1244.
63. Hildebolt CF, Pilgram TK, Yokoyama-Crothers N, Vannier MW, Dotson M, Muckerman J, Hauser J, Cohen S, Kardaris EE, Hanes P, Shrout MK, Civitelli R. Alveolar bone height and postcranial bone mineral density: negative effects of cigarette smoking and parity. J Periodontol 2000: 71: 683-689.
64. Holick M. High prevalence of vitaminD inadequacy and implications for health. Mayo Clin Proc 2006: 81: 353-373.
65. Holick M. Vitamin D deficiency. N Engl J Med 2007: 357: 266-281.
66. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, Petruschke RA, Chen E, de Papp AE. Prevalence of vitaminD inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005: 90: 3215-3224.
67. International Society of Clinical Densitometry 2007. 2007 Official positions and pediatric offical positions of the international society for clinical densitometry. West Hartford, CT: International Society for Clinical Densitometry, 2007 (http://iscd.org/Visitors/pdfs/ISCD2007OfficialPositions-Combined--AdultandPediatric.pdf).
68. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SAA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings ST, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O'Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Watawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D, for the Women's Health Initiative Investigators. Calcium plus vitaminD supplementation and the risk of fractures. N Engl J Med 2006: 354: 669-683.
69. Jacobs R, Ghyselen J, Koninckx P, van Steenberghe D. Long-term bone mass evaluation of mandible and lumbar spine in a group of women receiving hormone replacement therapy. Eur J Oral Sci 1996: 104: 10-16.
70. Jeffcoat M. Osteoporosis: a possible modifying factor in oral bone loss. Ann Periodontol 1998: 3: 312-321.
71. Jeffcoat M. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006: 21: 349-353.
72. Jeffcoat M, Lewis C, Reddy M, Wang C, Redford M. Post-menopausal bone loss and its relationship to oral bone loss. Periodontol 2000 2000: 23: 94-102.
73. Jeffcoat M, Reddy M. Alveolar bone loss and osteoporosis: evidence for a common mode of therapy using the bisphosphonate alendronate. In: Davidovitch Z. The biological mechanisms of tooth eruption, resorption and replacement by implants. Boston, MA: Harvard Society for the Advancement of Orthodontics, 1996: 365-373.
74. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005: 16: S3-S7.
75. Jonasson G, Bankvall G, Killaridis S. Estimation of skeletal bone mineral density by means of the trabecular pattern of the alveolar bone, its interdental thickness, and the bone mass of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002: 92: 346-352.
76. Kanis J, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001: 12: 989-995.
77. Kanis J, Melton LJ 3rd, Christiansen C, Johnston C, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994: 9: 1137-1141.
78. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ III, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, Van Staa T, Watts NB, Yoshimura N. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007: 18: 1033-1046.
79. Katz R. The RCI revisited after 15years: used, reinvented, modified, debated, and natural logged. J Public Health Dent 1996: 56: 28-34.
80. Kaukonen J, Karaharju E, Porras M, Lüthje P, Jakobsson A. Functional recovery after fractures of the distal forearm. Analysis of radiographic and other factors affecting the outcome. Ann Chir Gynaecol 1988: 77: 27-31.
81. Kazakia G, Majumdar S. New imaging technologies in the diagnosis of osteoporosis. Rev Endocr Metab Disord 2006: 7: 67-74.
82. Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol 2007: 21: 109-122.
83. Kemmler W, Engelke K, Lauber D, Weineck J, Hensen J, Kalender W. Exercise effects on fitness and bone mineral density in early postmenopausal women: 1-year EFOPS results. Med Sci Sports Exerc 2002: 34: 2115-2123.
84. Kemmler W, Engelke K, von Stengel S, Weineck J, Lauber D, Kalender W. Long-term four-year exercise has a positive effect on menopausal risk factors: the Erlangen Fitness Osteoporosis Prevention Study. J Strength Cond Res 2007: 21: 232-239.
85. Klotzbuecher C, Ross P, Landsman P, Abbott T, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000: 15: 721-739.
86. Kribbs PJ. Comparison of mandibular bone in normal and osteoporotic women. J Prosthet Dent 1990: 63: 218-222.
87. Kribbs P, Chesnut CH, Ott S, Kilcoyne R. Relationships between mandibular and skeletal bone in an osteoporotic population. J Prosthet Dent 1989: 62: 703-707.
88. Kribbs P, Chesnut CH, Ott S, Kilcoyne R. Relationships between mandibular and skeletal bone in a population of normal women. J Prosthet Dent 1990: 63: 86-89.
89. Kribbs P, Smith D, Chesnut CH. Oral findings in osteoporosis. Part I: measurement of mandibular bone density. J Prosthet Dent 1983: 50: 576-579.
90. Kribbs P, Smith D, Chesnut CH. Oral findings in osteoporosis. PartII: relationship between residual ridge and alveolar bone resorption and generalized skeletal osteopenia. J Prosthet Dent 1983: 50: 719-724.
91. Lane N. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006: 194: S3-S11.
92. Lata P, Elliott M. Patient assessment in the diagnosis, prevention, and treatment of osteoporosis. Nutr Clin Pract 2007: 22: 261-275.
93. Lewiecki E. Nonresponders to osteoporosis therapy. J Clin Densitom 2003: 6: 307-314.
94. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favur M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB, for the Alendronate PhaseIII Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995: 333: 1437-1443.
95. Ludvigsson J, Michaelsson K, Ekbom A, Montgomery S. Coeliac disease and the risk of fractures - a general population-based cohort study. Aliment Pharmacol Ther 2007: 25: 273-285.
96. Lundstrom A, Jendle J, Stenstrom B, Toss G, Ravald N. Periodontal conditions in 70-year-old women with osteoporosis. Swed Dent J 2001: 25: 89-96.
97. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, for the HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007: 357: 1799-1809.
98. Ma J, Johns R, Stafford R. Americans are not meeting current calcium recommendations. Am J Clin Nutr 2007: 85: 1361-1366.
99. Maciaszek J, Osiński W, Szeklicki R, Stemplewski R. Effect of tai chi on body balance: randomized controlled trial in men with osteopenia or osteoporosis. Am J Chin Med 2007: 35: 1-9.
100. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003: 349: 523-534.
101. Marques M, da Silva M, Manzi F, Cesar-Neto J, Nociti FJ, Barros S. Effect of intermittent PTH administration in the periodontitis-associated bone loss in ovariectomized rats. Arch Oral Biol 2005: 50: 421-429.
102. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996: 312: 1254-1259.
103. Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003: 61: 1115-1117.
104. Marx R, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005: 63: 1567-1575.
105. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Wasnich RD, Greenwald M, Kaufman J-M, Chesnut CH, Reginster J-Y. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001: 344: 333-340.
106. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, for the AMG162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006: 354: 821-831.
107. McKeever C, McIlwain H, Greenwald M, Gupta N, Jayawardene S, Huels G, Roberts M. An estradiol matrix transdermal system for the prevention of postmenopausal bone loss. Clin Ther 2000: 22: 845-857.
108. Migliorati C. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003: 21: 4253-4254.
109. Miller P. Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Rev Endocr Metab Disord 2006: 7: 75-89.
110. Moayyeri A, Ahmadi-Abhari S, Hossein-nezhad A, Larijani B, Soltani A. Bone mineral density and estimated height loss based on patients' recalls. Osteoporos Int 2006: 17: 834-840.
111. National Center for Complementary and Alternative Medicine. Coral calcium consumer advisory 2004. Available at: http://nccam.nih.gov/news/alerts/coral/coral.htm. (Accessed on 9th March 2011)
112. National Osteoporosis Foundation. The state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation, 2002.
113. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington DC: National Osteoporosis Foundation, 2003.
114. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008.
115. National Osteoporosis Foundation. Fast Facts. Available at: http://www.nof.org/node/40.
116. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH, Mellstrom D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001: 344: 1434-1441.
117. Nevitt M, Cummings S. Type of fall and risk of hip and wrist fractures: the study of osteoporotic fractures. J Am Geriatr Soc 1993: 41: 1226-1234.
118. Nguyen N, Ahlborg H, Center J, Eisman J, Nguyen T. Residual lifetime risk of fractures in women and men. J Bone Miner Res 2007: 22: 781-788.
119. Nishimura I, Hosokawa R, Atwood D. The knife-edge tendency in mandibular residual ridges in women. J Prosthet Dent 1992: 67: 820-826.
120. North American Menopause Society. The role of calcium in peri- and postmenopausal women: position statement of the North American Menopause Society. Menopause 2006: 13: 859-861.
121. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 2006: 13: 340-367.
122. O'Neill T, Felsenberg D, Varlow J, Cooper C, Kanis J, Silman A. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996: 11: 1010-1018.
123. Orwig D, Chan J, Magaziner J. Hip fracture and its consequences: differences between men and women. Orthop Clin North Am 2006: 37: 611-622.
124. Orwoll E. Osteoporosis in men. Endocrinol Metab Clin North Am 1998: 27: 349-367.
125. Parker M, Gillespie W, Gillespie L. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 2005: CD001255.
126. Payne JB, Reinhardt RA, Nummikoski PV, Patil KD. Longitudingal alveolar bone loss in postmenopausal osteoporotic/osteopenic women. Osteoporos Int 1999: 10: 34-40.
127. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008: 19: 811-818.
128. Recker R. Calcium absorption and achlorhydria. N Engl J Med 1985: 313: 70-73.
129. Reddy MS, Geurs NC, Wang IC, Liu PR, Hsu YT, Jeffcoat RL. Mandibular growth following implant restoration: does Wolff's law apply to residual ridge resorption? Int J Periodontics Restorative Dent 2002: 22: 315-321.
130. Reeve J, Kröger H, Nijs J, Pearson J, Felsenberg D, Reiners C, Schneider P, Mitchell A, Ruegsegger P, Zander C, Fischer M, Bright J, Henley M, Lunt M, Dequeker J. Radial cortical and trabecular bone densities of men and women standardized with the European Forearm Phantom. Calcif Tissue Int 1996: 58: 135-143.
131. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2year results from the MOBILE study. Ann Rheum Dis 2006: 65: 654-661.
132. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000: 11: 83-91.
133. Reszka A, Rodan G. Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003: 5: 65-74.
134. Rocha M, Nava L, Vázquez de la Torre C, Sánchez-Márin F, Garay-Sevilla M, Malacara J. Clinical and radiological improvement of periodontal disease in patients with type2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial. J Periodontol 2001: 72: 204-209.
135. Ruggiero S, Mehrotra B, Rosenberg T, Engroff S. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004: 62: 527-534.
136. Sambrook PN, Cameron ID, Chen JS, Summing RG, Lord SR, March LM, Schwarz J, Seibel MJ, Simpson JM. Influence of fall related factors and bone strength on fracture risk in the frail elderly. Osteoporos Int 2007: 18: 603-610.
137. Sambrook P, Cooper C. Osteoporosis. Lancet 2006: 367: 2010-2018.
138. Samuelson EJHM. Epidemiology of osteoporosis. Curr Rheumatol Rep 2006: 8: 76-83.
139. Santamaria M, Suaid F, Casati M, Nociti F, Sallum A, Sallum E. Coronally positioned flap plus resin-modified glass ionomer restoration for the treatment of gingival recession associated with non-carious cervical lesions: a randomized controlled clinical trial. J Periodontol 2008: 79: 621-628.
140. Shoback D. Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab 2007: 92: 747-753.
141. Sikon A, Thacker H, Carey J, Deal C, Licata A. Secondary osteoporosis: are we recognizing it? J Womens Health (Larchmt) 2006: 15: 1174-1183.
142. Silverman S, Gold D, Cramer J. Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J 2007: 100: 1214-1218.
143. Siris E, Delmas P. Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application. Osteoporos Int 2008: 19: 383-384.
144. Southard KA, Southard TE. Comparison of digitized radiographic alveolar features between 20- and 70-year-old women. A preliminary study. Oral Surg Oral Med Oral Pathol 1992: 74: 111-117.
145. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitaminD and fluoride. Washington DC: National Academy Press, 1997.
146. Straub D. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract 2007: 22: 286-296.
147. Streckfus CF, Johnson RB, Nick T, Tsao A, Tucci M. Comparison of alveolar bone loss, alveolar bone density and second metacarpal bone density, salivary and gingival crevicular fluid interleukin-6 concentrations in healthy premenopausal and postmenopausal women on estrogen therapy. J Gerontol A Biol Sci Med Sci 1997: 52: M343-M351.
148. Swanenburg J, de Bruin E, Stauffacher M, Mulder T, Uebelhart D. Effects of exercise and nutrition on postural balance and risk of falling in elderly people with decreased bone mineral density: randomized controlled trial pilot study. Clin Rehabil 2007: 21: 523-534.
149. Takaishi Y, Miki T, Nishizawa Y, Morii H. Clinical effect of etidronate on alveolar pyorrhoea associated with chronic marginal periodontitis: report of four cases. J Int Med Res 2001: 29: 355-365.
150. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003: 61: 1238-1239.
151. Tezal M, Wactawski-Wende J, Grossi SG, Ho AW, Dunford R, Genco RJ. The relationship between bone mineral density and periodontitis in postmenopausal women. J Periodontol 2000: 71: 1492-1498.
152. Tosteson ANA, Melton LJ III, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008: 19: 437-447.
153. Turner C. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002: 13: 97-104.
154. Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath JJ, Norman AW, Scragg R, Whiting SJ, Willett WC, Zitterman A. The urgent need to recommend an intake of vitaminD that is effective. Am J Clin Nutr 2007: 85: 649-650.
155. Wactawski-Wende J, Grossi SG, Trevisan M, Genco RJ, Tezal M, Dunford RG, Ho AW, Hausmann E, Hreshchyshyn MM. The role of osteopenia in oral bone loss and periodontal disease. J Periodontol 1996: 67: 1076-1084.
156. Wactawski-Wende J, Hausmann E, Hovey K, Trevisan M, Grossi S, Genco RJ. The association between osteoporosis and alveolar crestal height in postmenopausal women. J Periodontol 2005: 77: 2116-2124.
157. Wang J, Goodger N, Pogrel M. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003: 61: 1104-1107.
158. Watts N. Understanding the Bone Mass Measurement Act. J Clin Densitom 1999: 2: 211-217.
159. Wayne PM, Kiel DP, Krebs DE, Davis RB, Savetsky-German J, Connelly M, Burning JE. The effects of tai chi on bone mineral density in postmenopausal women: a systematic review. Arch Phys Med Rehabil 2007: 88: 673-680.
160. von Wowern N, Klausen B, Kollerup G. Osteoporosis: a risk factor in periodontal disease. J Periodontol 1994: 65: 1134-1138.
161. Youm T, Koval K, Kummer F, Zuckerman J. Do all hip fractures result from a fall? Am J Orthop 1999: 28: 190-194.